The Vita Coco Company (COCO) Falls 6.6% Despite Strong Quarter

The Vita Coco Company (COCO) is down 6.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The immediate catalyst is not fully clear because the company reported a strong second quarter and raised full-year guidance. This could be because investors focused instead on deal-related dilution and integration risk after Vita Coco closed its Copra acquisition and filed a resale shelf tied to stock issued in that transaction, while some traders may also have been taking profits after a sharp run in the shares.

Details:

Vita Coco reported second-quarter 2026 net sales of $216 million, up 28.1%, with gross margin at 48.7%, net income of $49 million, and adjusted EBITDA of $67 million.

The company increased 2026 guidance to net sales of $790 million to $805 million and adjusted EBITDA of $154 million to $161 million, including the contribution from Copra.

On July 22, Vita Coco closed the acquisition of Copra, paying $175 million upfront, with 80% funded in cash and the remainder in Vita Coco common stock, plus a possible earnout in 2029.

A same-day shelf registration covered up to 467,071 shares originally issued in connection with the Copra deal, which may have added concern about near-term selling pressure even though the filing itself does not mean all shares will be sold immediately.

Sources:

The Vita Coco Company, SEC, MarketChameleon

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$COCO Insider Trading Activity

$COCO insiders have traded $COCO stock on the open market 49 times in the past 6 months. Of those trades, 0 have been purchases and 49 have been sales.

Here’s a breakdown of recent trading of $COCO stock by insiders over the last 6 months:

IRA LIRAN has made 0 purchases and 6 sales selling 390,000 shares for an estimated $29,913,096.
MARTIN ROPER (Chief Executive Officer) has made 0 purchases and 11 sales selling 250,000 shares for an estimated $12,751,816.
JONATHAN BURTH (Chief Operating Officer) has made 0 purchases and 9 sales selling 180,000 shares for an estimated $12,069,200.
MICHAEL KIRBAN (Executive Chairman) has made 0 purchases and 3 sales selling 100,000 shares for an estimated $6,300,000.
JANE PRIOR (Chief Marketing Officer) has made 0 purchases and 3 sales selling 50,000 shares for an estimated $2,645,922.
KENNETH SADOWSKY has made 0 purchases and 6 sales selling 29,500 shares for an estimated $1,856,698.
JOHN D LEAHY sold 27,300 shares for an estimated $1,533,869
ES CHARLES VAN (Chief Commercial Officer) has made 0 purchases and 4 sales selling 14,045 shares for an estimated $950,817.
JANE CECIL MORREAU sold 15,000 shares for an estimated $808,650
COREY BAKER (Chief Financial Officer) has made 0 purchases and 5 sales selling 10,000 shares for an estimated $580,500.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$COCO Hedge Fund Activity

We have seen 140 institutional investors add shares of $COCO stock to their portfolio, and 119 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

BLACKROCK, INC. added 3,099,480 shares (+84.3%) to their portfolio in Q1 2026, for an estimated $141,460,267
WASATCH ADVISORS LP removed 1,420,129 shares (-38.6%) from their portfolio in Q2 2026, for an estimated $93,927,332
FULLER & THALER ASSET MANAGEMENT, INC. removed 1,381,657 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $63,058,825
CONGRESS ASSET MANAGEMENT CO added 1,207,102 shares (+inf%) to their portfolio in Q2 2026, for an estimated $79,837,726
MARSHALL WACE, LLP added 714,028 shares (+132.2%) to their portfolio in Q1 2026, for an estimated $32,588,237
STATE STREET CORP added 681,317 shares (+65.0%) to their portfolio in Q1 2026, for an estimated $31,095,307
PRICE T ROWE ASSOCIATES INC /MD/ removed 550,445 shares (-47.9%) from their portfolio in Q1 2026, for an estimated $25,122,309

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$COCO Congressional Stock Trading

Members of Congress have traded $COCO stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $COCO stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 03/03.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$COCO Analyst Ratings

Wall Street analysts have issued reports on $COCO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Evercore ISI Group issued a "Outperform" rating on 04/30/2026

To track analyst ratings and price targets for $COCO, check out Quiver Quantitative's $COCO forecast page.

$COCO Price Targets

Multiple analysts have issued price targets for $COCO recently. We have seen 5 analysts offer price targets for $COCO in the last 6 months, with a median target of $75.0.

Here are some recent targets:

Michael Lavery from Piper Sandler set a target price of $74.0 on 07/09/2026
Chris Carey from Wells Fargo set a target price of $85.0 on 05/18/2026
Robert Ottenstein from Evercore ISI Group set a target price of $75.0 on 04/30/2026
Kaumil Gajrawala from Jefferies set a target price of $78.0 on 04/30/2026
Eric Serotta from Morgan Stanley set a target price of $57.0 on 02/24/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.